KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Payables (2020 - 2025)

Ginkgo Bioworks Holdings' Payables history spans 6 years, with the latest figure at $10.6 million for Q4 2025.

  • For Q4 2025, Payables fell 25.43% year-over-year to $10.6 million; the TTM value through Dec 2025 reached $10.6 million, down 25.43%, while the annual FY2025 figure was $10.6 million, 25.43% down from the prior year.
  • Payables reached $10.6 million in Q4 2025 per DNA's latest filing, down from $10.7 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $35.3 million in Q1 2022 to a low of $1.4 million in Q1 2021.
  • Average Payables over 5 years is $13.8 million, with a median of $11.2 million recorded in 2025.
  • Peak YoY movement for Payables: soared 2379.71% in 2022, then crashed 58.26% in 2025.
  • A 5-year view of Payables shows it stood at $8.2 million in 2021, then increased by 27.62% to $10.5 million in 2022, then fell by 10.79% to $9.3 million in 2023, then surged by 51.98% to $14.2 million in 2024, then decreased by 25.43% to $10.6 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's Payables are $10.6 million (Q4 2025), $10.7 million (Q3 2025), and $11.2 million (Q2 2025).